Purple Biotech
PPBT
15 hedge funds and large institutions have $224K invested in Purple Biotech in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
3,657% more call options, than puts
Call options by funds: $263K | Put options by funds: $7K
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
7% more funds holding
Funds holding: 14 → 15 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
6% less capital invested
Capital invested by funds: $240K → $224K (-$15.3K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Simplex Trading
Chicago,
Illinois
|
+$37.1K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$20.6K |
| 3 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
+$7.5K |
| 4 |
Morgan Stanley
New York
|
+$2.25K |
| 5 |
AAS
Ameritas Advisory Services
Lincoln,
Nebraska
|
+$1.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$57.3K |
| 2 |
Fisher Asset Management
Camas,
Washington
|
-$44K |
| 3 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$20.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.75K |
| 5 |
FA
Fiduciary Alliance
Greenville,
South Carolina
|
-$4.49K |
PPBT Hedge Fund Activity: Q1 2023 in Review
15 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q1 2023, worth a combined $224K — down 6.4% from $240K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PPBT positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Simplex Trading, opening a new position worth an estimated $37.1K. The largest seller was Citadel Advisors, cutting an estimated $57.3K.
- 15 institutional investors held Purple Biotech (PPBT) as of Q1 2023, up from 14 in Q4 2022.
- Funds reported $224K of Purple Biotech stock for Q1 2023, down 6.4% quarter-over-quarter.
- 4 funds opened new Purple Biotech positions in Q1 2023 and 3 closed out, a net change of +1 holder.
- The largest Purple Biotech buyer in Q1 2023 was Simplex Trading, an estimated $37.1K added.
- The largest Purple Biotech seller in Q1 2023 was Citadel Advisors, an estimated $57.3K sold.
Based on aggregated 13F filings for Q1 2023.